Skip to main content
Site Search
Investors Home
News Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
SEC Filings
All Filings
Quarterly Results
Annual Reports & Proxies
Analyst Coverage
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
RSS Feeds
News Releases
Investors Home
News Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
SEC Filings
All Filings
Quarterly Results
Annual Reports & Proxies
Analyst Coverage
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
RSS Feeds
Normal
Get News Alerts by RSS
(opens in new window)
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
12/16/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12/13/2019
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
12/12/2019
plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer
12/11/2019
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
12/02/2019
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
12/02/2019
Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries
11/06/2019
Puma Biotechnology Reports Third Quarter 2019 Financial Results
11/05/2019
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
11/04/2019
Puma Biotechnology to Present at the Credit Suisse Healthcare Conference
10/23/2019
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
10/03/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
10/02/2019
FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Download
PDF format download (opens in new window)
09/25/2019
Puma Biotechnology to Present at Cantor Global Healthcare Conference
Download
PDF format download (opens in new window)
09/11/2019
Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Download
PDF format download (opens in new window)
09/05/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
09/04/2019
Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer
Download
PDF format download (opens in new window)
09/03/2019
Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Download
PDF format download (opens in new window)
09/03/2019
FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases
Download
PDF format download (opens in new window)
08/08/2019
Puma Biotechnology Reports Second Quarter 2019 Financial Results
Download
PDF format download (opens in new window)
08/06/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
07/25/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
07/24/2019
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Download
PDF format download (opens in new window)
07/16/2019
Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer
Download
PDF format download (opens in new window)
07/03/2019
Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019
Download
PDF format download (opens in new window)
07/01/2019
Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Download
PDF format download (opens in new window)
06/05/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
06/04/2019
Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting
Download
PDF format download (opens in new window)
06/02/2019
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
Download
PDF format download (opens in new window)
05/29/2019
Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference
Download
PDF format download (opens in new window)
05/09/2019
Puma Biotechnology Reports First Quarter 2019 Financial Results
Download
PDF format download (opens in new window)
05/08/2019
Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019
Download
PDF format download (opens in new window)
05/03/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
04/25/2019
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Download
PDF format download (opens in new window)
04/09/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
04/04/2019
Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations
Download
PDF format download (opens in new window)
04/01/2019
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
Download
PDF format download (opens in new window)
03/28/2019
Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019
Download
PDF format download (opens in new window)
03/18/2019
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting
Download
PDF format download (opens in new window)
03/18/2019
Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Download
PDF format download (opens in new window)
03/14/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
03/05/2019
Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Download
PDF format download (opens in new window)
02/28/2019
Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
Download
PDF format download (opens in new window)
02/15/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)
02/13/2019
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Download
PDF format download (opens in new window)
02/04/2019
Puma Biotechnology Announces Litigation Victory with Jury’s Decision
Download
PDF format download (opens in new window)
01/11/2019
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada
Download
PDF format download (opens in new window)
01/03/2019
Puma Biotechnology to Present at J. P. Morgan Healthcare Conference
Download
PDF format download (opens in new window)
01/02/2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Download
PDF format download (opens in new window)